AIM: The objective of the present study was to prepare a trivalent inactivated vaccine of Newcastle disease virus (NDV), H5N1, and H9N2 viruses. MATERIALS AND METHODS: Three monovalent and a trivalent vaccines were prepared by emulsifying inactivated NDV (LaSota strain), reassortant H5N1, and H9N2 viruses with Montanide ISA 71 oil adjuvant. Parameters used for evaluation of the efficacy of the prepared vaccines in specific pathogen-free chickens were cellular immunity assays (blastogenesis, interferon gamma, interleukin 1 [IL1], and IL6), humoral immunity by hemagglutination inhibition, protection percentage, and shedding. RESULTS: A single immunization with trivalent vaccine-enhanced cell-mediated immunity as well as humoral immune response with 90% protection against challenges with highly pathogenic avian influenza (HPAI) H5N1 and low pathogenic (LP) avian influenza H9N2 viruses with 100% protection after challenge with NDV. CONCLUSION: Development and evaluation of the trivalent vaccine in the study reported the success in preparation of a potent and efficacious trivalent vaccine which is a promising approach for controlling HPAI H5N1, LP H9N2, and ND viral infections.
AIM: The objective of the present study was to prepare a trivalent inactivated vaccine of Newcastle disease virus (NDV), H5N1, and H9N2 viruses. MATERIALS AND METHODS: Three monovalent and a trivalent vaccines were prepared by emulsifying inactivated NDV (LaSota strain), reassortant H5N1, and H9N2 viruses with Montanide ISA 71 oil adjuvant. Parameters used for evaluation of the efficacy of the prepared vaccines in specific pathogen-free chickens were cellular immunity assays (blastogenesis, interferon gamma, interleukin 1 [IL1], and IL6), humoral immunity by hemagglutination inhibition, protection percentage, and shedding. RESULTS: A single immunization with trivalent vaccine-enhanced cell-mediated immunity as well as humoral immune response with 90% protection against challenges with highly pathogenic avian influenza (HPAI) H5N1 and low pathogenic (LP) avian influenza H9N2 viruses with 100% protection after challenge with NDV. CONCLUSION: Development and evaluation of the trivalent vaccine in the study reported the success in preparation of a potent and efficacious trivalent vaccine which is a promising approach for controlling HPAI H5N1, LP H9N2, and ND viral infections.
Authors: Adam J Karpala; John Bingham; Karel A Schat; Li-Mei Chen; Ruben O Donis; John W Lowenthal; Andrew G D Bean Journal: J Interferon Cytokine Res Date: 2011-01-01 Impact factor: 2.607
Authors: Jincun Zhao; Christine Wohlford-Lenane; Jingxian Zhao; Erica Fleming; Thomas E Lane; Paul B McCray; Stanley Perlman Journal: J Virol Date: 2012-08-22 Impact factor: 5.103
Authors: Isabella Monne; Hussein A Hussein; Alice Fusaro; Viviana Valastro; Mohamed M Hamoud; Rabab A Khalefa; Shahin N Dardir; Moustafa I Radwan; Ilaria Capua; Giovanni Cattoli Journal: Influenza Other Respir Viruses Date: 2012-07-02 Impact factor: 4.380
Authors: Ghazi Kayali; Ahmed Kandeil; Rabeh El-Shesheny; Ahmed S Kayed; Mokhtar M Gomaa; Asmaa M Maatouq; Mahmoud M Shehata; Yassmin Moatasim; Ola Bagato; Zhipeng Cai; Adam Rubrum; Mohamed A Kutkat; Pamela P McKenzie; Robert G Webster; Richard J Webby; Mohamed A Ali Journal: Emerg Infect Dis Date: 2014-04 Impact factor: 6.883